Various other BET inhibitors have entered early clinical trials in patients with R/R AML, including TEN-010 (NCT02308761), GSK525762 (NCT01943851), and CPI-0610 (NCT02158858). This evidence concerns the gene DNER and acute myeloid leukemia.